|Related Categories||Antibiotics, Antibiotics A to Z, Antibiotics N-S, Antibiotics by Application, Antifungal,|
|solubility||ethanol: soluble2 mM|
|Gene Information||human ... FKBP1A(2280)|
Live Chat and Frequently Asked Questions are available for this Product.
A macrocyclic triene antibiotic that binds to and inhibits the molecular target of rapamycin (mTOR). It forms a complex with FKBP12 that binds to and inhibits the molecular target of rapamycin (mTOR). Rapamycin is a potent immunosuppressant and has anticancer activity.
Certificate of Analysis
Proliferating cells require the biosynthesis of structural components for biomass production and for genomic replication. This requires a reprogramming of the metabolic pathways to ensure nutrients s...
Keywords: Aerobic, Antitumor agents, Apoptosis, Cancer, Degradations, Environmental, Gene expression, Glycolysis, Growth factors, Metabolic Pathways, Metabolism, Metabolites, Nucleotide Synthesis, PAGE, Pentose phosphate pathway, Phosphorylations
The PDK1–PKB/Akt axis represents one of the most actively researched cell signaling pathways. This protein kinase cascade is known to play a central role in mediating the actions of a range of stimul...
Keywords: Apoptosis, Atomic absorption spectroscopy, Cancer, Cell proliferation, Cell signaling, Diabetes, Gene expression, Growth factors, Inflammation, Metabolism, Myristoylations, Phosphorylations, Reversible addition-fragmentation chain transfer polymerizations
Traditionally, cancer has been viewed as a disease in which environmental or endogenous events induce mutations to critical oncogenes and tumor suppressor genes within a normal cell. The clinical man...
BioFiles 2008, 3.5, 4.
Keywords: Angiogenesis, Apoptosis, Asymmetric synthesis, Cancer, Catalysis, Cell culture, Cell division, Cell proliferation, Clinical, DNA replication, Degradations, Eliminations, Environmental, Gastrointestinal, Gene expression, Growth factors, Ligands, Metabolic Pathways, Phosphorylations, Poisons, Transcription, Transfection, transformation
From The Cover: Bifurcation Of Insulin Signaling Pathway In Rat Liver: MTORC1 Required For Stimulation Of Lipogenesis, But Not Inhibition Of Gluconeogenesis Li, S., et al. Proc. Natl. Acad. Sci. U. S. A. 107, 3441-3446, (2010)
Loss of hydrophobic motif and activation loop phosphorylation is a consequence and not the mechanism of S6 kinase 1 inhibition by rapamycin. Beigh MA, Showkat M, Hussain MU, et al. J. Biol. Regul. Homeost. Agents 27(2), 399-408, (2013)
Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). Xie J, Zhang X, Fang BZ, et al. Chin. Med. Sci. J. 28(2), 127-8, (2013)
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Pourdehnad M, Truitt ML, Siddiqi IN, et al. Proc. Natl. Acad. Sci. U. S. A. 110(29), 11988-93, (2013)
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Campone M, Bachelot T, Gnant M, et al. Eur. J. Cancer 49(12), 2621-32, (2013)
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Chinnaiyan P, Won M, Wen PY, et al. Int. J. Radiat. Oncol. Biol. Phys. 86(5), 880-4, (2013)
Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation. Shin YJ, Hyon JY, Choi WS, et al. Invest. Ophthalmol. Vis. Sci. 54(7), 4452-8, (2013)
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. Demetri GD, Chawla SP, Ray-Coquard I, et al. J. Clin. Oncol. 31(19), 2485-92, (2013)
PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. Berdichevsky Y, Dryer AM, Saponjian Y, et al. J. Neurosci. 33(21), 9056-67, (2013)
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. Natsuaki M, Kozuma K, Morimoto T, et al. J. Am. Coll. Cardiol. 62(3), 181-90, (2013)
Early vascular healing with biodegradable polymer coated sirolimus-eluting coronary stent implantation: assessed by optical coherence tomography results at 4-month follow-up. Abhyankar A, Prajapati J, Reddy S, et al. Minerva Cardioangiol. 61(3), 313-22, (2013)
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Tinker AV, Ellard S, Welch S, et al. Gynecol. Oncol. 130(2), 269-74, (2013)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?